Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Hits Above The Belt With Zantac Purchase

This article was originally published in The Tan Sheet

Executive Summary

Boehringer Ingelheim looks to expand its therapeutic territory up the GI tract with a $509.5 mil. purchase of U.S. rights to the acid reducer Zantac (ranitidine) from Johnson & Johnson and the Pfizer Consumer Healthcare business
Advertisement

Related Content

Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales
Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales
Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
EC extends J&J/Pfizer look
EC eyes J&J-Pfizer
Chattem Acquires “Great Brands” In Wake Of J&J’s Pfizer Purchase
Chattem Acquires “Great Brands” In Wake Of J&J’s Pfizer Purchase
J&J Picks Up Listerine, Nicorette With $16.6 Bil. Purchase Of Pfizer OTCs

Topics

Advertisement
UsernamePublicRestriction

Register

PS099841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel